Charles Farthing

Learn More
BACKGROUND The continuing, randomised, multinational, phase IIB POWER 1 and 2 studies aim to evaluate efficacy and safety of darunavir in combination with low-dose ritonavir in treatment-experienced(More)
BACKGROUND GS-9137 is a potent low-nanomolar strand transfer inhibitor of HIV-1 integrase. METHODS The antiviral activity, tolerability, pharmacokinetics, and pharmacodynamics of GS-9137 were(More)